Reimbursement and Support

We focus on access so you can focus on health.

At Genentech, we develop therapies for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them.

Rituxan® Access Solutions is here to help you and your patients when a Genentech medicine is prescribed. Our knowledgeable and experienced Specialists can help you navigate the access and reimbursement process. Each patient’s insurance and financial situation is unique. We offer a full range of programs and services to meet the needs of you and your patients.

Rituxan Access Solutions: Service structure

  • Help with benefits and coverage issues
    • Benefits investigation
    • Prior authorization
    • Recertification
  • Help with reimbursement issues
    • Denials and appeals
    • Billing and coding information
  • Genentech® Access to Care Foundation (GATCF) support for qualifying uninsured and rendered uninsured patients
  • Referrals to co-pay assistance foundations
  • Genentech therapy-specific co-pay cards
  • Access to treatment support programs
  • Additional support resources
  • Online Resources
  • Communication assistance services
    • Translation services
    • Telephone to telephone typewriter (TTY) services
  • Product spoilage and replacement information
  • Glossary of access and reimbursement terms
  • The Genentech BioOncology Co-pay Card helps eligible patients reduce their out-of-pocket co-pay expenses
  • CancerCare is a leading national non-profit organization offering counseling, education and practical help free of charge to anyone affected by cancer
  • Living with Lymphoma is a comprehensive service and information resource for all members of the non-Hodgkin's lymphoma community – regardless of whether they are RITUXAN patients

At Rituxan Access Solutions, we work hard to make information you need about coverage and reimbursement easily available:

Copay Card

Genentech BioOncology Co-pay Card

See if your patients are eligible.

View Now
Prescribing Information including Medication Guide

Prescribing Information including Medication Guide (PDF)

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.


RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)

RITUXAN is not recommended for use in patients with severe, active infections.

Important Safety Information



  • Infusion Reactions: RITUXAN administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue RITUXAN infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions
  • Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN
  • Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with RITUXAN, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with RITUXAN. Discontinue RITUXAN and concomitant medications in the event of HBV reactivation
  • Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving RITUXAN

Warnings and Precautions

Tumor Lysis Syndrome

  • Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12−24 hours after the first infusion of RITUXAN in patients with NHL. A high number of circulating malignant cells (≥25,000/mm3) or high tumor burden, confers a greater risk of TLS. Administer aggressive intravenous hydration and anti hyperuricemic therapy in patients at high risk for TLS


  • Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of RITUXAN-based therapy. Discontinue RITUXAN for serious infections and institute appropriate anti infective therapy


  • Discontinue infusions for serious or life threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of RITUXAN for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina


  • Severe, including fatal, renal toxicity can occur after RITUXAN administration in patients with NHL. Monitor closely for signs of renal failure and discontinue RITUXAN in patients with a rising serum creatinine or oliguria

Bowel Obstruction and Perforation

  • Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving RITUXAN in combination with chemotherapy. Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur


  • The safety of immunization with live viral vaccines following RITUXAN therapy has not been studied and vaccination with live virus vaccines is not recommended

Laboratory Monitoring

  • Obtain complete blood counts (CBC) prior to each RITUXAN course

Additional Important Safety Information

  • The most common Grade 3 or 4 adverse reactions in clinical trials of NHL and CLL were infusion reactions, neutropenia, leukopenia, anemia, thrombocytopenia, and infections. Additionally, lymphopenia and lung disorder were seen in NHL trials; and febrile neutropenia, pancytopenia, hypotension, and hepatitis B were seen in CLL trials
  • The most common adverse reactions (incidence ≥25%) in clinical trials of NHL and CLL were infusion reactions. Additionally, fever, lymphopenia, chills, infection, and asthenia were seen in NHL trials; and neutropenia was seen in CLL trials
  • Pregnancy: Category C. There are no adequate and well-controlled studies of rituximab in pregnant women

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

You may report side effects to the FDA at (800) FDA-1088 or

You may also report side effects to Genentech at (888) 835-2555.